TRANSKRYPCJA 🔗
WEBVTT
00:00:01.040 --> 00:00:04.080
Welcome to the WTR Small Cap Spotlight Podcast.
00:00:04.240 --> 00:00:08.000
I'm your host, Tim Gerdeman, co-founder of Water Tower Research.
00:00:08.320 --> 00:00:14.960
In today's podcast episode, I'm joined by Tommy Barletta, co-founder and managing partner of Aldous Institutional.
00:00:15.279 --> 00:00:20.559
Tommy operates on the crossroads between financial markets, policy, and politics.
00:00:20.800 --> 00:00:26.480
Tommy has a bachelor's degree from Wake Forest and Politics and an MBA from Georgetown.
00:00:26.800 --> 00:00:39.840
Aldous Institutional is an independent research provider that leverages decades of policy expertise with Washington and Wall Street relationships to provide clients with actionable ideas and insightful events.
00:00:40.079 --> 00:00:50.240
Their platform combines timely, moderated small group events with key stakeholders and policymakers with market commentary on DC-driven catalyst.
00:00:50.640 --> 00:01:00.799
This differentiated approach and their extensive experience at the crossroads of markets and policy are vital for clients navigating both macro and issue-specific catalyst.
00:01:01.200 --> 00:01:14.159
Given the imminent midterm elections in the U.S., I thought it would be timely to have Tommy share his views of likely outcomes and subsequent impacts on policies that could impact both institutional and retail investors moving forward.
00:01:14.480 --> 00:01:21.359
Tommy, it was rather serendipitous that you and I randomly met in Miami Beach weeks ago at a brokerage firm biotech event luncheon.
00:01:21.519 --> 00:01:26.480
Welcome to today's podcast and thank you for joining to share your insights with our audience.
00:01:27.599 --> 00:01:30.159
Tim, thank you so much for having me and for having us.
00:01:30.239 --> 00:01:32.959
And again, as you mentioned, great to reconnect.
00:01:33.040 --> 00:01:44.480
Uh albeit the last time we spoke was a bit warmer and the and the weather was a bit nicer, but always happy to chat um about you know kind of the intersection of healthcare policy uh markets and of course this election that is now uh six days away.
00:01:44.799 --> 00:01:46.879
Touche on the weather uh arbitrage.
00:01:47.040 --> 00:01:53.040
So uh Tommy, affordability and cost of living issues reportedly define the 2026 midterms.
00:01:53.280 --> 00:02:03.840
Polling points to Democrats taking the House and even potentially taking the Senate, and a first 100 days agenda centered on helping voters afford rising health care costs.
00:02:04.000 --> 00:02:12.879
Can you please expand on these topics for our listeners with an eye toward how the outcome will impact Wall Street and investors, beginning with the likely election outcome?
00:02:13.280 --> 00:02:13.840
Sure, Tim.
00:02:14.080 --> 00:02:15.360
It's a great place to start.
00:02:15.599 --> 00:02:36.319
So, uh, you know, for those on the line, since the passage of the one big beautiful bill or OBBB as it's
Load full transcript
referred to commonly in Washington, and the emergence of the kind of blue wave thesis, right, of Democrats winning the House and the Senate, this election has been really closely watched by uh, you know, healthcare investors, especially those levered to hospitals, managed care and services, right?
00:02:36.479 --> 00:02:44.400
All of the sectors that were negatively impacted by what is nearly a trillion dollars of cuts in the OBB to the healthcare space.
00:02:44.719 --> 00:02:58.400
And so as we think about affordability being a key theme, as you mentioned, and and healthcare affordability being tied really closely to that, you know, this has become in some ways a healthcare election, and the outcome is very much a coverage election, right?
00:02:58.479 --> 00:03:03.680
What would the outcomes be in the next two years that would change uh the outlook for increased coverage?
00:03:03.759 --> 00:03:07.039
And that has a lot of read-through, of course, into some of the sector impact.
00:03:07.199 --> 00:03:11.039
To do a bit of the scenario analysis, you know, we can just talk about the House and Senate, right?
00:03:11.120 --> 00:03:19.199
The House, uh I, you know, we have fielded very few questions about the outlook for the House uh, you know, in the past couple months, you know, pretty much consensus that it flipped.
00:03:19.280 --> 00:03:24.080
We'll be looking at a Speaker Jeffries um, you know, very likely in in January.
00:03:24.159 --> 00:03:27.520
And I think the question is how hard, how hard do they run up the score?
00:03:27.680 --> 00:03:29.039
Is it 220, 230?
00:03:29.199 --> 00:03:33.919
But I think the important point there is it's going to be a very functional and cohesive House majority.
00:03:34.000 --> 00:03:37.680
I think Jeffries has done a good job of kind of gathering all the folks together.
00:03:37.840 --> 00:03:49.439
They've done a number of uh kind of working groups on the healthcare side to kind of bring consensus across the party as they think about what the agenda is both for 2026, 2027, and obviously a look ahead to 2028.
00:03:49.599 --> 00:03:51.280
The Senate's more interesting, of course, right?
00:03:51.439 --> 00:04:01.199
I think the that's really where the blue wave kind of turned from maybe some pickups to, hey, you know, we could have uh, you know, leader, leader Schumer um after the election.
00:04:01.439 --> 00:04:04.000
You know, I think as far as outcomes, you've got a wide range.
00:04:04.080 --> 00:04:09.919
You've got some folks out there saying like Nate Silver up as high as in the 70s, I think, uh prediction markets in the 60s.
00:04:10.000 --> 00:04:22.879
You know, we're probably closer to 50-50 with a slight lean towards uh, you know, Democrats probably uh, you know, win the win the majority, but I think it's important to stress that you know that's the likely outcome, but the tails could be pretty wide, right?
00:04:23.040 --> 00:04:28.000
You could very much see a scenario where um, you know, Republicans hang on to the majority, right?
00:04:28.079 --> 00:04:37.600
You could see a scenario where Democrats get a slight majority, or the bottom falls out and Republicans, you know, are looking or Democrats are looking at you know kind of low to mid-50s seats, right?
00:04:37.759 --> 00:04:39.040
So let's just go through that a bit.
00:04:39.199 --> 00:04:42.079
So I think uh Georgia and North Carolina are gone, right?
00:04:42.160 --> 00:04:52.160
I think if you look at the the polling and the spend, uh, you know, I think the consensus is, you know, a Democratic senator in in North Carolina and John Ossoff hanging on in Georgia.
00:04:52.399 --> 00:05:00.800
I think there's been a lot of coverage in the news about the kind of Midwest, uh farm belt states, Iowa, Nebraska, uh Kansas even.
00:05:01.199 --> 00:05:03.439
You know, I think that's in the kind of tail scenario.
00:05:03.519 --> 00:05:08.160
If those go down, they're gonna all go together, and and then you have really the bottom falling out for Republicans.
00:05:08.240 --> 00:05:15.360
So what leaves us with like, you know, Maine, Ohio, Texas, and potentially Alaska as as potential flips.
00:05:15.439 --> 00:05:25.920
And, you know, the polling data is is is you know better for Democrats, but I think you we're kind of faced with the same uh uh challenges that we've seen of the last elections, right?
00:05:26.000 --> 00:05:31.759
Are the underrepresented people who don't pick up the phone, are they under underrepresented polling, do they turn out?
00:05:31.920 --> 00:05:36.560
Is Democratic enthusiasm enough to push Democrats above that like kind of 47%?
00:05:37.199 --> 00:05:49.199
Or are there a bunch of Trump voters who will be encouraged to come out in the midterms, which traditionally they underperform if you look at governors' races last year in New Jersey and Virginia, um, and hand the Senate control over to Democrats?
00:05:49.279 --> 00:05:56.639
But I think to kind of put a point on it, Tim, you know, house flipping and slight lean towards Democrats gaining uh, you know, control of the Senate.
00:05:57.120 --> 00:05:59.519
Really dynamic and wildly nuanced.
00:05:59.600 --> 00:06:05.839
Um so moving on, Tommy, what companies are likely to be the winners and the losers resulting from your predicted election outcome?
00:06:06.160 --> 00:06:07.040
Yeah, sure, Tim.
00:06:07.120 --> 00:06:13.279
So I I think as I mentioned, this is this election is all about uh the OBB and coverage.
00:06:13.360 --> 00:06:18.879
I'll touch on pharma in a bit because it's worth talking about as as we think about next year and potential risks.
00:06:19.040 --> 00:06:24.959
But at the end of the day, if we see a blue wave, the sentiment for hospitals is going to be vastly improved, right?
00:06:25.120 --> 00:06:28.079
You're gonna, there's lots of discussion of what do we delay in the OBB?
00:06:28.319 --> 00:06:30.399
Do the tax credits come back, et cetera, et cetera.
00:06:30.560 -->
00:06:36.480
Now, the challenge for the space is do you have to endure several more challenging quarters of operational issues, right?
00:06:36.560 --> 00:06:44.560
Which we saw HCA talk about uh yesterday, October 27th, um, before you get policy relief, but that's where the sentiment's gonna be.
00:06:44.720 --> 00:06:59.360
Similarly, for those exchange-levered insurers, I think you'll see a bit of an uplift over some optimism on pushback to uh some of the OBB provisions or re-re-reintroducing a version of those enhanced freedom tax credits that expired at the start of 2025.
00:06:59.519 --> 00:07:09.519
But again, you could see a very challenging start to the year from a coverage perspective, from an enrollment perspective, um, which you didn't see this year, because I think some people were hanging on thinking that the credits are going to be extended.
00:07:09.680 --> 00:07:14.560
So I think it's like positive sentiment, but the execution and the timing is crucial.
00:07:14.720 --> 00:07:21.920
Um, I think as far as like sectors that have a bit to be kind of kind of concerned about, and not necessarily losers, Medicare Advantage is one, right?
00:07:22.079 --> 00:07:23.519
I think we'll talk about this in a moment.
00:07:23.680 --> 00:07:25.759
The administration still has a lot of leverage to pull.
00:07:25.839 --> 00:07:30.959
Um, you know, to the extent there's pay fors, Medicare Advantage is probably on the list of paying for other priorities.
00:07:31.120 --> 00:07:32.959
So something to be mindful of.
00:07:33.120 --> 00:07:38.000
But at the end of the day, um, you know, it's it's I put it more in the middle column there.
00:07:38.639 --> 00:07:40.560
I think pharma is interesting, right?
00:07:40.639 --> 00:07:49.920
I think if you look back like a year or two years ago, we were worried about MFN deals, uh uh the HHS secretary banning GLP ones and all those pricing concerns.
00:07:50.160 --> 00:07:57.199
Well, the industry's done a fabulous job of engaging Washington, and so I think some of that, they're they're kind of will be somewhat untouched by the election outcome.
00:07:57.360 --> 00:08:08.079
But I just wanted to note how much the picture's changed, especially now that we have effectively a more functioning FDA, which is crucial for both large cap but as well as uh, you know, kind of medium and small cap there.
00:08:08.399 --> 00:08:26.560
On the kind of negative side for pharma, I do think there's going to be a bit of headline risk, especially as Democrats take back the majority on oversight, bringing in the CEOs of Lilly and Pfizer and folks who signed MFN deals and pulling up in front of Congress to talk about the terms, why weren't they disclosed, right?
00:08:26.720 --> 00:08:34.559
It's all part of the Democratic strategy to expose some of the issues and some of their concerns with the Trump administration agenda, but it's going to be using companies to make that point.
00:08:34.639 --> 00:08:35.840
So I'd be concerned
there.
00:08:36.080 --> 00:08:42.159
The other thing from like a more of a generalist perspective is I think you'll hear a lot of Trump deal making, you know, that kind of thesis.
00:08:42.320 --> 00:08:45.039
And he's the president, he's very unpredictable.
00:08:45.200 --> 00:08:47.120
So I wouldn't rule that out entirely.
00:08:47.200 --> 00:08:52.559
But I think some people might default to, well, Democrats agree with drug pricing, Trump agrees to drug pricing.
00:08:52.639 --> 00:08:53.759
Is there something to be had there?
00:08:53.919 --> 00:09:02.480
So I could see some concern in the pharma space about that, but I don't think that's that that's a real risk that's going to play out over the course of the next uh two years.
00:09:02.879 --> 00:09:09.039
Those are fascinating data points that our institutional and retail investor uh listener base will love to process.
00:09:09.200 --> 00:09:14.000
So, regardless of the election outcome, obviously Trump remains in office for two more years.
00:09:14.159 --> 00:09:15.759
What can we expect, Tommy?
00:09:16.159 --> 00:09:16.559
Of course.
00:09:16.639 --> 00:09:17.840
So I mentioned this earlier.
00:09:17.919 --> 00:09:21.440
Uh Medicare Advantage is still something that the administration is very focused on.
00:09:21.600 --> 00:09:25.279
They have control over many of the policy levers to shape the future of the program.
00:09:25.440 --> 00:09:34.799
Whether it's the stars, which uh are subject to a lot of litigation, um, but you know, changes in stars drove uh significant uh, you know, kind of out outperformance by Humana.
00:09:35.120 --> 00:09:42.879
Um they were a big beneficiary of the recent um their internal improvements uh drove some you know improvements in their star ratings, which is important for payment.
00:09:43.039 --> 00:09:52.480
Um, but I think the administration still has some things that they want to do, whether it's on risk adjustment, whether it's on stars, whether it's testing additional models, to kind of get the program to a better place.
00:09:52.720 --> 00:09:55.759
I think that's an area where, again, they control many of the policy levers.
00:09:55.919 --> 00:10:00.320
So that's an area where having them in power, having them run HHS and CMS is important.
00:10:00.639 --> 00:10:02.080
Waste, fraud, and abuse.
00:10:02.399 --> 00:10:05.919
The administration feels very strongly that that is a core issue.
00:10:06.000 --> 00:10:08.080
Um they've leaned into into the election, right?
00:10:08.159 --> 00:10:13.200
And you've seen a number of press releases about uh removing folks from the exchanges that may not have been qualified.
00:10:13.360 --> 00:10:14.399
I think that continues.
00:10:14.559 --> 00:10:27.120
That probably has more read-through for, I'll say subsectors, you know, potentially uh clinical laboratories, durable medical equipment, um, you know, uh home-based home care providers levered to the Medicaid program, right?
00:10:27.279 --> 00:10:30.000
Again, that's an area where the administration has a lot of authority.
00:10:30.080 --> 00:10:37.440
Um and then I'd say lastly, you know, it's it's kind of a smaller one, but but very large companies involved is is kidney care and dialysis.
00:10:37.600 --> 00:10:42.480
The administration last week rolled out a pretty significant um plan to improve kidney care.
00:10:42.720 --> 00:10:49.360
Um, and there are a number of things that kind of were pointed at uh the competitive nature of having two large dialysis organizations.
00:10:49.440 --> 00:10:51.519
And so that's something that I think they're focused on.
00:10:51.600 --> 00:10:55.279
It dovetails nicely with um the Make America Healthy again agenda.
00:10:55.440 --> 00:11:03.759
And there are a number of folks from Trump kind of 1.0 who they spent a lot of time, Alex Azar spent a lot of time on this topic, who are kind of holdovers and still involved and they could push that forward.
00:11:03.840 --> 00:11:11.679
So again, more of a smaller on a relative basis to Humana and Managed Care, but um something that we're watching very closely as well.
00:11:12.159 --> 00:11:13.120
Okay, thank you for that.
00:11:13.200 --> 00:11:22.799
Um can you speak to expectations surrounding the future of Medicare for all and follow that by discussing the pharma industry and likely DC drug price policies ahead?
00:11:23.279 --> 00:11:24.080
Absolutely.
00:11:24.320 --> 00:11:33.919
So, you know, the blue wave uh was accompanied by uh enthusiasm, but also concern that um, you know, you see um Mr.
00:11:34.159 --> 00:11:42.480
Al Said in Michigan win his race, and then you have the the kind of proof point that moving further to the left politically is advantageous for Democrats.
00:11:42.559 --> 00:11:49.279
And if they perform really well, well, that signals a more leftward turn of a candidate in the 2028 presidential election, right?
00:11:49.440 --> 00:11:54.639
I don't think anyone was under the impression that if there's a blue wave, that we're gonna enact Medicare for all in the next two years.
00:11:55.759 --> 00:12:04.720
But I think the concern and markets' discounting mechanisms were concerned about, you know, nominee AOC versus like Andy Bashir in Kentucky, right?
00:12:04.799 --> 00:12:06.639
Like the leftward wing would win out.
00:12:06.799 --> 00:12:12.240
And so that prompted a lot of concern, a lot of you know client focus on what does Medicare for all look like?
00:12:12.399 --> 00:12:15.600
Is that gonna be the central pillar of the uh of for the Democratic Party?
00:12:15.759 --> 00:12:18.080
Again, the primary start in 2027.
00:12:18.159 --> 00:12:21.200
So it's literally the day after the election, we're gonna be talking about the Democratic primary.
00:12:21.440 --> 00:12:23.519
But I I think the details are really important.
00:12:23.759 --> 00:12:34.000
I mentioned earlier uh Hakeem Jeffries brought together some Democratic leaders, including uh Congresswoman AOC, to discuss kind of
options for expanding coverage.
00:12:34.240 --> 00:12:45.440
The discussion has been a lot about universal coverage, not universal care, which I think is an important distinction and offers some um potential positivity for managed care.
00:12:45.600 --> 00:12:50.960
Like at the end of the day, the last time Democrats did a coverage expansion, it relied heavily on managed care companies.
00:12:51.039 --> 00:13:02.879
And I think maybe different this time, but I have a hard time believing we're gonna see the end of uh you know managed care as part of a democratic strategy to increase um coverage.
00:13:03.120 --> 00:13:04.399
Two other things I'll note there.
00:13:04.639 --> 00:13:10.799
One, I think as a near-term win, you can see Democrats focusing a lot on expanding coverage to vision, hearing, and dental, right?
00:13:10.879 --> 00:13:14.480
That's not covered currently under the Medicare program in limited spaces for hearing aids.
00:13:14.639 --> 00:13:24.559
I think that's something where if you want to talk about a Trump deal making, like does he get together with like Elizabeth Warren and Bernie Sanders and talk about giving something to seniors, fits very nicely with giving folks$90 checks.
00:13:24.639 --> 00:13:27.759
So that's something I will keep an eye on near-term, that is kind of a bridge.
00:13:27.919 --> 00:13:39.440
The second topic that's getting a little more run, and again, low likelihood of coming across the finish line, but I would watch in the context of this Medicare for all conversation is um lowering the Medicare age, right?
00:13:39.600 --> 00:13:47.919
That obviously comes with a lot of policy, you know, kind of puts and takes, but it's something that maybe is like a middle ground and says, hey, more people can get into the program.
00:13:48.080 --> 00:13:50.480
And yes, it costs money, but maybe there's some benefits there.
00:13:50.559 --> 00:13:56.320
So something kind of to watch that's beneath that big headline, like, you know, Democrats are coming for your healthcare, et cetera.
00:13:56.559 --> 00:14:06.879
On the pharma pricing side, you know, as I said, I I go back to when uh the CEO of Lilly uh went down to Mar-a-Lago right after the the the 2024 elections, right?
00:14:07.039 --> 00:14:12.559
That pharma has performed incredibly well and navigated this environment politically very astutely, right?
00:14:12.720 --> 00:14:18.879
The MFN deals, I think, are largely not events, um, and you know, is specific to Lily and Novo.
00:14:19.120 --> 00:14:25.919
We've got a federally mandated coverage of of GLP ones, which I don't think is ending um this demo is going on for two years, it's not it's not ending.
00:14:26.000 --> 00:14:28.240
I can't imagine we're taking things away from seniors.
00:14:28.399 --> 00:14:33.519
Um I think there will be some concern about or conversation about expansion of the IRA, right?
00:14:33.600 --> 00:14:34.960
The Inflation Reduction Act.
00:14:35.039 --> 00:14:42.480
Um, I think
there'll be some concern about back to your question about what the Trump administration can do, how do they handle the Part B drugs that are coming as part of the negotiation?
00:14:42.639 --> 00:14:47.519
But I I I think in some sense, we kind of know what the potential outcomes are for IRA.
00:14:47.600 --> 00:14:48.320
There's nothing new.
00:14:48.480 --> 00:14:57.039
And so and I think a lot of investors are comfortable with kind of like the program works, we know how it does, it's predictable, we can model that, um, you know, et cetera, et cetera.
00:14:57.440 --> 00:14:57.840
Great.
00:14:58.000 --> 00:14:59.519
Uh, this has been awesome, Tommy.
00:14:59.600 --> 00:15:06.720
Um, wrapping up, what are investors wanting you to watch most closely in DC in the weeks and months ahead, out of curiosity?
00:15:07.120 --> 00:15:07.600
Absolutely.
00:15:07.679 --> 00:15:10.000
And thanks for the question, Tim, and the time today.
00:15:10.159 --> 00:15:17.840
So uh first and foremost, as I mentioned, as soon as the election's over, we're gonna be focused on uh funding the federal government past December 11th.
00:15:18.000 --> 00:15:37.919
So threshold issue, there's a kind of key question in there whether we do like a short-term punt, which would which would lead to like a March catalyst again, or something where that's the clear-the-deck thesis, where everyone wants to start fresh, Democrats don't want to be dealing with a spending fight or shut down in the early part of their tenure, so push things out until September of 2027.
00:15:38.320 --> 00:15:43.679
I think that's really the outlook there is really TBD and truly depends on the election and the posture of the president.
00:15:43.840 --> 00:15:52.159
In addition, there's been conversations about, you know, during the lame doc when Republicans still control level levers of power, increasing the debt limit.
00:15:52.320 --> 00:16:00.799
The thesis being, hey, let's do something on the debt limit before we have to negotiate with Democrats and, you know, and maybe do waste fraud and abuse, cutting spending, et cetera, et cetera.
00:16:00.879 --> 00:16:04.320
You hear Ron Johnson, who's the the chairman of the budget committee, talk about that a lot.
00:16:04.480 --> 00:16:10.559
I think it's a great idea, but I think you've got a lot of attendance issues in both the House and Senate that's going to make that very challenging to execute.
00:16:10.639 --> 00:16:20.320
But something we're keeping an eye on because if the debt limit is taken care of, that removes a catalyst for um action on those OBB repeal replace provisions, right?
00:16:20.399 --> 00:16:22.080
Congress doesn't do anything unless there's a deadline.
00:16:22.159 --> 00:16:26.720
So you if you're kind of bullish on that outcome, you want to see deadlines in 27.
00:16:26.960 --> 00:16:34.879
The other thing I think that that you know kind of ebbs and flows, but is is getting more and more conversation, the status of US-China relations as it pertains to biotech.
00:16:35.039 --> 00:16:39.679
You we had um the Coins Act last week, which I think most investors were comfortable with the outcome.
00:16:39.759 --> 00:16:48.159
Um, but that's something where I think you got to be cognizant or aware that that's an area where there's bipartisan consensus, the concern about the rise of the Chinese biotech sector.
00:16:48.399 --> 00:17:01.679
And while, again, the proposed rule last week seemed to be uh, you know, kind of a non-event, I think it's an area where folks are are are constantly kind of concerned that that could be a kind of a tail risk given the amount of relationships we have between U.S.
00:17:01.759 --> 00:17:05.519
biotech and and uh the the companies in in China.
00:17:06.000 --> 00:17:06.240
Great.
00:17:06.480 --> 00:17:10.400
Well, thank you, Tommy uh Barletta from Aldis Institutional for joining us today.
00:17:10.480 --> 00:17:14.799
I was kind of laughing as you were speaking, thinking about the days when I used to be a Wall Street analyst.
00:17:14.880 --> 00:17:17.599
I always prided myself on giving actionable ideas.
00:17:17.839 --> 00:17:23.519
I think investors will get at least a dozen or two dozen actionable ideas just from what you said in about 20 minutes time.
00:17:23.599 --> 00:17:25.519
So this has been awesome, and thank you for your time.
00:17:26.240 --> 00:17:27.119
Thank you again, Tim.
00:17:27.359 --> 00:17:28.720
Always appreciate the opportunity.
00:17:31.039 --> 00:17:46.640
Thank you for listening, and don't forget to subscribe, as well as visiting www.watertowerresearch.com to stay up to speed on the company's small cap written research reports, podcasts, fireside chats, industry specific symposiums, and conference schedules.
00:17:47.039 --> 00:17:51.839
We will see you next time for another edition of the WTR Small Cap Spotlight Podcast.
00:17:52.319 --> 00:17:57.440
Finally, a special thanks to the producer and editor of the podcast, Krista Fitzpatrick.